Pharmacogenomics and Cardiovascular Disease

Pharmacogenomics and Cardiovascular Disease

Emily K. Dornblaser (University of New England, USA), Craig P. Worby (University of New England, USA) and Daniel Alan Brazeau (University of New England, USA)
DOI: 10.4018/978-1-5225-2092-4.ch009


Cardiovascular disease is one of the most prevalent disease states in the U.S. and contributes substantially to overall morbidity and mortality. The ability to effectively optimize the treatment of cardiovascular disease has a significant impact on overall disease prevention and treatment. This chapter discusses the relationship between genetic variations and their impact on medications used for the treatment of cardiovascular disorders. Key medications that are susceptible to genetic variation have been identified. The chapter describes the mechanisms by which genetic variation may contribute to altered medication concentrations or effects and briefly reviews the place in therapy for the cardiovascular medications. In addition, this chapter reviews current clinical literature to determine the overall impact these variations may have on clinical outcomes.
Chapter Preview


It has been a little over a 15 years since the publication of the initial draft of the human genome (Venter et al. 2001; Lander et al. 2001). Estimates for the final cost to sequence the “first” human genome range from $500 million to $1 billion. Since the completion of this first genome sequencing, technologies have undergone two revolutions first with massively parallel sequencing in the 2005 and recently with nanopore sensing technologies that hold out the hope of single molecule sequencing. As these next generation sequencing technologies become readily available, genome sequencing costs has decreased and sequence yields increased exponentially. In large part due to availability of high-throughput sequencing technologies it has become possible to begin to assess and catalogue human genetic variation. In an analysis of sequence data from protein coding regions (exomes) of 60,706 individuals Lek, et al. (2016) have identified over 3,000 genes which are likely loss of function variants; importantly 72% of these identified genes have no established disease phenotype at this time. The ultimate identification and delineating of these variants in human populations are critical to understanding the underlying genetic causes of human disease and drug response.

This revolution in genomic technologies as well as the attendant advances in bioinformatics has led to the appeal for prevention and treatment strategies based upon the individual characteristics of the patient, now referred to as “Precision Medicine”.

Complete Chapter List

Search this Book: